Clinical results in the treatment of respiratory infections with moxifloxacin.

Respiratory infections are a common source of morbidity and mortality, with pneumonia being the number one cause of death from infectious disease in Western industrialized countries. Initial antibiotic therapy of upper and lower respiratory infections is often empiric, being directed at the pathogens that are most likely to be present. Leading pathogens in respiratory infections are S. pneumoniae, H. influenzae and M. catarrhalis, which have developed considerable resistance problems against previous standard antibiotics like beta-lactams, macrolides and tetracyclines in the last decade. Newly developed quinolones such as moxifloxacin combine enhanced in vitro activity against Gram-positive bacteria with maintenance of activity against Gram-negative organisms. Three comparative, prospective, randomized, double-blind studies in the treatment of community acquired sinusitis, AECB and CAP demonstrated equal or higher efficacy of moxifloxacin in comparison to standard antibiotic therapies.
AuthorsH Lode, A Lubasch, M Raffenberg, H Mauch
JournalDrugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 36 Issue 4 Pg. 245-53 (Apr 2000) ISSN: 1699-3993 [Print] Spain
PMID12879120 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: